Headlines about Evogene (NASDAQ:EVGN) have trended somewhat positive on Tuesday, according to Accern Sentiment Analysis. The research firm identifies positive and negative media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Evogene earned a media sentiment score of 0.14 on Accern’s scale. Accern also assigned news coverage about the biotechnology company an impact score of 47.0302314150217 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Separately, ValuEngine downgraded shares of Evogene from a “sell” rating to a “strong sell” rating in a research report on Friday, March 2nd.
Evogene (NASDAQ EVGN) traded down $0.12 during trading on Tuesday, hitting $3.61. 23,799 shares of the company were exchanged, compared to its average volume of 9,413. Evogene has a 52 week low of $2.66 and a 52 week high of $5.74. The firm has a market cap of $98.88, a P/E ratio of -4.57 and a beta of 0.65.
Evogene (NASDAQ:EVGN) last released its earnings results on Wednesday, February 28th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.21) by ($0.03). Evogene had a negative net margin of 616.33% and a negative return on equity of 27.15%. The company had revenue of $0.73 million for the quarter. analysts predict that Evogene will post -0.75 EPS for the current year.
Evogene Company Profile
Evogene Ltd. (Evogene) is a biotechnology company for the improvement of crop productivity. The Company is engaged in developing seed traits for improved yield and abiotic stress tolerance, seed traits for biotic stress resistance, herbicides and bio-stimulants. The Company operates a seed business under its subsidiary Evofuel Ltd.
Receive News & Ratings for Evogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene and related companies with MarketBeat.com's FREE daily email newsletter.